Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- ...

Please provide your email address to receive an email when new articles are posted on . However, this finding did not reach statistical significance, the researchers noted. “This is the first ...

Please provide your email address to receive an email when new articles are posted on . Fidaxomicin was the most rational fiscal strategy compared with vancomycin for Clostridium difficile-associated ...

Preventative oral vancomycin reduces the incidence of C. difficle during allogeneic hematopoietic stem cell transplantation, according to a study by Pittsburgh-based University of Pennsylvania ...

Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans. Now, a new study suggests that the leading antibiotic used to fight it ...

Fidaxomicin should be the antibiotic of choice when treating adults with Clostridioides difficile infection, according to new guidance from the Infectious Diseases Society of America and the Society ...

Fecal microbiota transplant might be considered for first-line treatment of Clostridioides difficile (C. diff), based on noninferiority findings from a randomized, open-label trial. A similar ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

September 15, 2010 (Boston, Massachusetts) — Fidaxomicin is superior to vancomycin in treating recurrences of gastrointestinal Clostridium difficile infection, according to a blinded randomized trial ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

Researchers conducted a phase II, randomized, double-blind, non-inferiority study including participants from 33 centers in the U.S. and Canada. The study includes patients with signs of C. diff ...

Clostridium difficile is the most common cause of nosocomial diarrhea in acute-care settings. Until now, the two available therapies for C. difficile-associated diarrhea (CDAD), vancomycin and ...